The Emergence of the Metabolic Syndrome with Menopause

MOLLY C. CARR

Division of Metabolism, Endocrinology, and Nutrition, University of Washington, Seattle, Washington 98195-6426

Women with the metabolic syndrome (central obesity, insulin resistance, and dyslipidemia) are known to be at especially high risk for cardiovascular disease (CVD). The prevalence of the metabolic syndrome increases with menopause and may partially explain the apparent acceleration in CVD after menopause. The transition from pre- to postmenopause is associated with the emergence of many features of the metabolic syndrome, including 1) increased central (intraabdominal) body fat; 2) a shift toward a more atherogenic lipid profile, with increased low density lipoprotein and triglycerides levels, reduced high density lipoprotein, and small, dense low density lipoprotein particles; 3) and increased glucose and insulin levels. The emergence of these risk factors may be a direct result of ovarian failure or, alternatively, an indirect result of the metabolic consequences of central fat redistribution with estrogen deficiency. It is unclear whether the transition to menopause increases CVD risk in all women or only those who develop features of the metabolic syndrome. This article will review the features of the metabolic syndrome that emerge with estrogen deficiency. A better understanding of these metabolic changes with menopause will aid in the recognition and treatment of women at risk for future CVD, leading to appropriate interventions. (*J Clin Endocrinol Metab* 88: 2404–2411, 2003)

THE RECENT RELEASE of data from the Women's Health Initiative has forced practitioners to reconsider their options for prevention of cardiovascular disease (CVD) in postmenopausal women (1). CVD risk increases after the menopause, which may be related to the substantial metabolic changes that occur as women transition from premenopause to postmenopause. In many women features of the metabolic syndrome (abdominal adiposity, insulin resistance, and dyslipidemia) emerge with estrogen deficiency. The aim of this article is to review the influence of menopause on the emergence of this constellation of cardiovascular risk factors known as the metabolic syndrome. A better understanding of these metabolic changes with menopause may help in the recognition of women at risk for future cardiovascular disease, leading to appropriate interventions.

Menopause

Menopause is best defined as the absence of menses for 12 consecutive months. Menstrual history is the most reliable indicator of the postmenopausal state, as specific hormonal measures, such as estradiol (E_2) and FSH levels both vary widely in the perimenopause during an individual menstrual cycle (2). The perimenopause has been defined as a period of menstrual irregularity and hormonal variability, beginning when menstrual cycle length changes from an established pattern into longer, shorter, or more variable cycles, with an average duration of 4 yr, ending 1 yr after the final menstrual period. This means that women can expect to have menstrual irregularities for approximately 4 yr before their final menses. Although it is commonly believed that E_2 levels fall gradually throughout the perimenopause, concentrations are preserved until relatively late in the perimenopausal period, as E_2 does not decline significantly until women experience at least 3 months of amenorrhea (2).

Cardiovascular disease (CVD) risk after menopause

CVD is the primary cause of death in women of westernized countries, with more than one in two women dying from CVD. However, atherosclerotic disease occurrence is distinct in men and women, as onset begins approximately 10 yr later in women than men, and myocardial infarction is uncommon until women reach their sixth decade (3). Premenopausal women appear to be protected from CVD compared with men of similar age. Although women below the age of 50 yr rarely develop CVD, by age 70 yr the incidence of CVD is equal in men and women, suggesting that estrogen deficiency causes a rapid acceleration in CVD risk.

Controversy exists about whether menopause increases the risk of CVD independent of normal aging. Some studies have demonstrated increased risk of CVD after menopause, and others have not (4). For example, Framingham investigators found a 4-fold increase in CVD in the 10 yr following natural menopause. Premature, surgically induced menopause has been shown to increase the risk for CVD (4). Yet the question of whether natural menopause is an independent risk factor for CVD has not been answered, as it is very difficult to design studies that can separate the effects of the normal aging process from menopause. Statistical adjustment for age or body weight in longitudinal studies may erase the influence of other closely related factors and underestimate the effect of estrogen deficiency on CVD risk. The metabolic and hormonal changes of menopause occur

over several years and vary widely among women. Also, CVD risk factors may be predictors of early menopause. Finally, it may be that estrogen deficiency increases CVD risk in only a subset of women who develop features of the metabolic syndrome, and this subset has not been well studied.

Studies assessing the relationship of menopause with measures of atherosclerosis have yielded interesting results. Sutton-Tyrrell *et al.* (5) showed that 45% of postmenopausal women (n = 294) had clinically significant carotid intima-media thickness (≥0.75 mm) compared with 16% of age-matched premenopausal women. Carotid intima-media thickness has been shown to be a strong predictor of CVD risk (6). Aortic calcification, a measure of atherosclerosis, was higher in postmenopausal women, and the extent of calcification increased with the number of postmenopausal years (7). Similarly, coronary artery calcium deposits in women, measured by computed tomography (CT), was half that in men until the age of 60 yr, when the difference decreased (8).

The relative importance of factors that influence cardiovascular risk in postmenopausal women are unknown. Alterations in lipid metabolism with estrogen deficiency are thought to be a substantial component of CVD risk in postmenopausal women (9), but there are also direct effects of estrogen deficiency on body fat distribution (central obesity), insulin action, the arterial wall, and fibrinolysis that may influence cardiovascular risk. These factors contribute to an increased prevalence of the metabolic syndrome in postmenopausal women compared with premenopausal women (10), and this postmenopausal worsening of the metabolic profile may contribute to the future risk of CVD.

The metabolic syndrome

The metabolic syndrome has received more focus as the updated Adult Treatment Panel III guidelines emphasize treatment of the metabolic syndrome in addition to lowering of low density lipoprotein (LDL) levels (11). The metabolic syndrome may not be a single disease entity, but, rather, a constellation of closely related risk factors that together convey substantially increased cardiovascular risk after accounting for traditional CVD risk factors (12). The features of the metabolic syndrome include the accumulation of visceral (abdominal) adiposity, insulin resistance, hypertension, and dyslipidemia (hypertriglyceridemia, reduced high density lipoprotein (HDL), and small dense LDL particles; Table 1) (13). The metabolic syndrome is estimated to affect approximately 20–30% of the middle-aged population (10), and prevalence appears to be increasing in the U.S. population with increasing obesity and sedentary lifestyle (14). Post-

menopausal status is associated with a 60% increased risk of the metabolic syndrome, even after adjusting for confounding variables, such as age, body mass index (BMI), household income, and physical inactivity (10). The risk of CVD attributed to the metabolic syndrome appears to be especially high in women, and it is estimated that half of all cardiovascular events in women are related to the metabolic syndrome (15).

Although syndrome X was initially coined by Gerald Reaven in 1988 (16), the features of the metabolic syndrome were first described by Vague (17) and have subsequently been called the insulin resistance syndrome, the central obesity syndrome, and the deadly quartet. Diagnostic criteria for the metabolic syndrome, as defined by the National Cholesterol Education Program Adult Treatment Panel III, are shown in Table 2; these easily obtained measures are useful for classifying patients (11).

The etiology of the metabolic syndrome is unknown, but is thought to be a combination of factors. Selby *et al.* (18) studied 1028 male twins and found greater concordance of dyslipidemic hypertension in monozygotic than dizygotic twins. Within the discordant monozygotic twin pairs, the twin with dyslipidemic hypertension weighed significantly more as an adult, implying an interaction between genetic and environmental influences on the manifestation of the metabolic syndrome (19). Many believe that the underlying pathophysiology of the metabolic syndrome is related to increased visceral obesity and insulin resistance (13).

Effects of menopause on body composition

Two patterns of body fat distribution have been observed, the accumulation of fat centrally, as intraabdominal fat (android or apple shape) and the accumulation of fat in the gluteo-femoral region (gynoid or pear shape; Fig. 1). The accumulation of fat in a central distribution (intraabdominal) has emerged as a cardiovascular risk factor independent of overall obesity (20). Android fat deposition is associated with a higher risk of diabetes, hypertriglyceridemia, small dense LDL particles, hypertension, and CVD (13). Estrogen promotes the accumulation of gluteo-femoral fat (21), and the loss of estrogen with menopause is associated with an increase in central fat (22). The sexual dimorphism in adipose tissue distribution may partially explain the greater CVD risk in men compared with premenopausal women.

Although it is commonly believed that menopause is as-

TABLE 1. Features of the metabolic syndrome

1. Central obesity
2. Insulin resistance
3. Dyslipidemia
   a. Elevated TG
   b. Small dense LDL particles
   c. Reduced HDL
4. High blood pressure
5. Hypercoaguable state
6. Proinflammatory state

TABLE 2. Diagnostic criteria for the metabolic syndrome (requiring three or more risk factors)

Risk factor	Defining level
Waist circumference	
Men	>102 cm (>40 inches)
Women	>88 cm (>35 inches)
Triglyceride	≥1.7 mmol/liter (≥150 mg/dl)
HDL	
Men	<1.0 mmol/liter (<40 mg/dl)
Women	<1.3 mmol/liter (<50 mg/dl)
Blood pressure	≥130/≥85 mm Hg
Fasting glucose	≥6.1 mmol/liter (≥110 mg/dl)

Data are from the Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III), *JAMA* 285:2486–2497, 2001.

FIG. 1. Patterns of body fat distribution.

sociated with weight gain, most studies do not reveal increases in BMI independent of normal aging (23, 24). Although it is estimated that middle-aged women gain approximately 0.55 kg (~1 lb)/yr, there does not appear to be an independent effect of menopause on body weight (25, 26). However, even in the absence of weight gain, body fat distribution changes across the menopause. Cross-sectional (27) and longitudinal studies (22, 28) have shown that the menopausal transition is associated with a preferential increase in abdominal adiposity, independent of the effect of age and total body adiposity. Poehlman *et al.* (22) prospectively compared women who became postmenopausal to age-matched controls who remained premenopausal and found that the transition to menopause was associated with an increase in the waist to hip ratio and total body fat. Abdominal fat, measured by CT scan, has also been shown to increase with menopause in both cross-sectional (29) and prospective studies (30). Visceral fat accumulation is thought by many to be the major determinant of the metabolic syndrome.

Women with high amounts of visceral fat have an excess of cardiovascular mortality and associated metabolic abnormalities (31). When Pascot *et al.* (32) matched women for abdominal fat (by CT scan) and menopausal status, the differences initially found in very low density lipoprotein (VLDL), LDL, HDL, large buoyant HDL$_2$ particles, LDL particle size, fasting glucose, C peptide, and blood pressure were

eliminated, implying that the differences in visceral fat and menopausal status accounted for the metabolic differences. Regional differences in adipose tissue lipoprotein lipase activity in postmenopause may account for the menopausal changes in fat accumulation, but results to date are conflicting (33, 34). Adiponectin, a novel adipocyte-derived peptide, may play a role in the metabolic syndrome, as concentrations are inversely related to obesity and insulin resistance. However, the only study evaluating adiponectin in menopause revealed no difference in pre- and postmenopausal women (35).

Menopause is also associated with reduced lean body mass (muscle) and this appears to be related to decreased physical activity (36). Lynch *et al.* (37) recently reported lower maximal oxygen consumption (VO$_2$ max) in sedentary postmenopausal (VO$_2$ max) women compared with sedentary age-matched premenopausal women and found an inverse relationship between visceral adiposity and maximal oxygen consumption. The reductions in exercise capacity and activity may contribute to the reduced lean body mass and increased central adiposity with menopause.

Effects of menopause on lipid metabolism

Although the association between abdominal adiposity and the constellation of lipid abnormalities is well known, the underlying pathophysiology is not clear. High amounts of abdominal fat are associated with increased insulin resistance, free fatty acid (FFA) levels, and decreased adiponectin (Fig. 2). These factors contribute to increased secretion of apolipoprotein B (apo B)-containing particles, leading to hypertriglyceridemia and increased hepatic lipase (HL) activity resulting in a predominance of small dense LDL particles and a reduction in large antiatherogenic HDL$_2$ particles. A similar pattern of lipid abnormalities emerges with menopause (Table 3).

Changes in LDL with menopause

Postmenopausal women have higher total cholesterol, LDL cholesterol, triglycerides (TG), and lipoprotein(a) [Lp(a)] levels and lower HDL cholesterol levels than premenopausal women (38–40). Although elevated LDL is not a component of the metabolic syndrome, LDL levels increase by 10–20% (23, 41) with menopause, and the greatest change


FIG. 2. The interaction of genetic and environmental factors influences the manifestation of the metabolic syndrome. High amounts of intraabdominal fat (IAF) are associated with increased insulin resistance (IR) and FFA levels, and decreased adiponectin. These factors contribute to increased secretion of apo B-containing particles, leading to hypertriglyceridemia and increased HL activity, which lead to a predominance of small dense LDL particles and a reduction in the large antiatherogenic HDL$_2$ particles.

TABLE 3. Lipoprotein changes with menopause (longitudinal studies)

Cohort size	Total cholesterol	LDL	HDL	Triglycerides
150	−	−	↓	−
18	−	↑	↓	↑
10	↑	↑	↓	↑
69	↑	↑	↓	↑
343	↑	ND	ND	↑

−, No significant change; ND, not done; ↑, significant increase; ↓, significant decrease. Data are from Lindquist (50), Matthews *et al.* (41), Jensen *et al.* (38), Poehlman *et al.* (23), and Do *et al.* (51).

TABLE 4. Percentage of women who maintain or change LDL size with menopause

	Premenopause		Postmenopause
51%	lbLDL	⇨	lbLDL
36%	lbLDL	⇨	sdLDL
13%	sdLDL	⇨	sdLDL

Data are from Austin *et al.* (43). lbLDL, Large, buoyant LDL; sdLDL, small, dense LDL.

in LDL concentration appears to occur early in the transition from premenopause to postmenopause (42). Apo B, the primary apolipoprotein of LDL particles, and other apo B-containing particles are also higher in postmenopausal compared with premenopausal women (40).

LDL particle composition also changes with menopause. The prevalence of small, dense LDL is low in premenopausal women (10–13%), but increases to 30–49% in postmenopausal women (39, 43, 44) (Table 4). LDL are comprised of a spectrum of particles that vary in size, density, chemical composition, and atherogenic potential. A preponderance of small, dense LDL is associated with an increased risk of myocardial infarction (45) as well as the severity of CVD (46). The risk of CVD is 3-fold higher in women with small, dense LDL than in those with large, buoyant LDL (45). Mackey *et al.* (47) recently showed by electron beam CT that postmenopausal women with high coronary calcium scores had smaller LDL particle size, higher LDL levels, and fewer large HDL_2 particles than postmenopausal women with low coronary calcium scores.

Changes in TG with menopause

Many longitudinal studies have shown that TG levels increase with the transition through the menopause (38), and the increase in TG also appears early in the postmenopausal period (42). Poehlman *et al.* (23) found that the prospective transition to postmenopause was associated with a 16% increase in TG. Although men generally have higher TG levels than women, TG increases in middle-age (between 40–69 yr) in women, but not in men (48), and TG appears to be a better predictor of CVD risk in women than in men (49). Lindquist (50) reported a prospective increase in TG levels in women who became postmenopausal during a 6-yr period, whereas there was no change in TG in the similarly aged women who remained either premenopausal or postmenopausal. Increasing TG with menopause may be related to the fact that TG levels are highly correlated with increasing abdominal fat content and insulin resistance.

Changes in HDL with menopause

Most studies show that total HDL levels fall slightly with menopause (23, 38, 41, 51), whereas others reveal no changes (52). Menopausal changes in HDL metabolism are more complex than the measurement of total HDL reveals, because the more antiatherogenic HDL_2 levels decrease (by 25%), whereas HDL_3 levels increase (26, 30, 40, 53). HDL_2 particles are the large, buoyant, and more cardioprotective subspecies of total HDL. The strong inverse relationship between HDL cholesterol and abdominal adiposity appears to be largely dependent on variations in HDL_2 levels (54).

Changes in Lp(a) with menopause

Lp(a), an LDL-like particle with structural homology to plasminogen, is not frequently measured in clinical practice, but has been shown to predict cardiovascular events in women independent of LDL levels (55). Lp(a) levels are primarily genetically determined, but several studies have now shown significant increases in Lp(a) levels (by 25–50%) with menopause (30, 56, 57). This rise in Lp(a) levels with menopause may reflect the fact that Lp(a) levels are sensitive to sex steroid hormones and return to premenopausal levels with estrogen replacement (57).

Changes in proteins of lipid metabolism with menopause

Proteins of lipid metabolism underlying the menopausal change in lipids have been evaluated in few studies. The increased prevalence of small, dense LDL with menopause may be explained by higher HL activity in postmenopausal women (30, 58). Endogenous estrogen levels are inversely associated with HL activity (59). HL hydrolyzes the TG and phospholipid in LDL and HDL and is one factor that determines the size and density of LDL and HDL particles (60). The higher the HL activity, the more TG and phospholipid hydrolyzed, resulting in smaller, denser more atherogenic lipoprotein particles. Lipoprotein lipase hydrolyzes TG in triglyceride-rich lipoproteins, generating FFA that can serve as an energy source or can be stored in adipocytes. We have recently shown a small, but significant, rise in lipoprotein lipase activity with the transition through menopause (unpublished observation). Cholesteryl ester transfer protein (CETP) catalyzes the exchange of cholesterol ester in HDL and LDL particles for TG in VLDL, and high CETP concentrations are associated with reduced HDL levels. Menopausal status does not appear to affect CETP activity (61). The mechanisms underlying the menopausal changes in lipid metabolism are not clear and require further study.

The perimenopausal changes in lipid metabolism reveal an overall shift toward a more atherogenic lipid profile with increased LDL and TG levels, reduced HDL_2 concentration, and smaller, denser LDL particles, similar to the metabolic syndrome. This classic dyslipidemia is closely associated with increasing amounts of visceral fat, which may explain why these features emerge with the menopause. It is likely that these adverse changes in lipid metabolism during the menopausal transition will contribute to future CVD risk.

Insulin resistance changes with menopause

Two of the most important pathophysiological components of the metabolic syndrome are increased visceral fat accumulation and insulin resistance. Abdominal obesity is closely associated with increased insulin resistance, compensatory hyperinsulinemia, and increased risk of type 2 diabetes, independent of an individual's total body fat content (62). The pathophysiology underlying the insulin-resistant state is complex. Insulin resistance, with inadequate compensatory hyperinsulinemia, diminishes the normal suppression of FFA arising from adipose tissue by insulin. The increased levels of FFA may impair peripheral glucose uptake, increase hepatic gluconeogenesis, and reduce hepatic clearance of insulin (13).

The literature to date is not clear as to whether menopause is associated with increased insulin resistance. What little data there are remain contradictory. Several groups have shown increased fasting insulin (22, 48) and increased fasting glucose levels (37, 63) in postmenopausal compared with premenopausal women, which would imply worsened insulin resistance with the menopause. However, insulin sensitivity is known to worsen with advancing age and increasing central obesity, making it difficult to tease out the effect of menopause from these processes. Studies using accurate measures of insulin resistance, such as the euglycemic-hyperinsulinemic clamp or the frequently sampled iv glucose tolerance test, are scarce (64–67).

Lindheim *et al.* (64) showed reduced insulin sensitivity (*i.e.* higher insulin resistance) in postmenopausal women compared with BMI-matched premenopausal women. However, others have shown no differences in insulin sensitivity in postmenopausal compared with premenopausal women (65, 66). DeNino *et al.* (67) compared measures of insulin resistance and visceral adipose tissue in age-grouped women ranging from 20–78 yr. They found that reduced insulin sensitivity did not appear until women were older than 60 yr and had accumulated levels of visceral fat that approximated the levels seen in men, suggesting a possible threshold effect of abdominal fat on insulin resistance (67).

Guthrie *et al.* (68) reported prospective data on 265 healthy perimenopausal women with normal fasting glucose. The group of women (16%) who developed impaired fasting glucose (≥6.1 mmol/liter) over the 5-yr period had higher baseline BMI, fasting glucose and insulin, waist circumference, and TG; lower HDL levels; as well as greater increases in BMI and insulin over the study period compared with women who maintained normal fasting glucose. There was no difference in menopausal status between the two groups; this implies that weight gain had a stronger influence on the development of impaired fasting glucose than menopause itself (68).

Effects of menopause on fibrinolytic and inflammatory markers

Markers of impaired fibrinolysis, plasminogen activator inhibitor-1 (PAI-1) and tissue plasminogen activator (tPA), and subclinical inflammation, C-reactive protein (CRP) and IL-6), are also associated with the metabolic syndrome and appear to play a role in the pathogenesis of CVD (69). Fibrinolytic activity is a balance between plasminogen activators (tPA) and inhibitors (PAI-1). Elevated PAI-1 activity causes prolonged clot lysis times and potentiates thrombosis. High PAI-1 activity is associated with high plasma levels of tPA antigen (which represents t-PA/PAI-1 complexes), which has been found to be independently associated with CVD in both men and women (70). PAI-1 is produced by liver and adipose tissue, particularly visceral adipose tissue (71), and is thought to be a marker of insulin resistance.

Postmenopausal women have higher levels of PAI-1 and tPA antigen than premenopausal women (72). Age-matched men have higher levels of tPA antigen than premenopausal women (73). These data imply that estrogen deficiency and increased visceral adiposity are associated with a decrease in fibrinolytic potential. Given that PAI-1 is positively associated with abdominal fat content and plasma TG, higher PAI-1 levels with menopause may be a marker of women at higher risk of CVD.

CRP is a marker of the presence and intensity of subclinical inflammation that independently predicts CVD risk in men and women (74). Like PAI-1, CRP is positively associated with total body fat mass and abdominal fat, and weight loss in postmenopausal women has been shown to reduce CRP levels by 32% (75). Sites *et al.* (76) recently found no differences in CRP between premenopausal (mean age, 47 yr) and early postmenopausal (mean age, 51 yr) women; however these healthy women may have had relatively few differences in atherosclerotic plaque burden.

IL-6 is a proinflammatory cytokine produced by macrophages and monocytes that induces the production of CRP, and elevated IL-6 levels are associated with increased risk of cardiovascular death (77). Recent data from the Women's Health Initiative revealed that higher baseline CRP and IL-6 levels predicted cardiovascular outcomes in apparently healthy older women (78). Several studies have shown higher IL-6 levels in postmenopausal compared with premenopausal women (79).

Treatment of the metabolic syndrome in women

Postmenopausal women who develop features of the metabolic syndrome should be aggressively treated to reduce CVD risk. Management guidelines suggest a combination of lifestyle modification and drug therapy. Until recently, hormone replacement therapy (HRT) was an option for treatment of the postmenopausal metabolic syndrome, because it improved many of the metabolic abnormalities (63). However, with the recent release of data from the estrogen-progestin arm of the Women's Health Initiative demonstrating increased CVD risk in HRT users, HRT is no longer recommended for preventative therapy of CVD (1).

Lifestyle modification

Weight loss and physical exercise are both mainstays of therapy, as they address the underlying etiology of the metabolic syndrome (visceral obesity and insulin resistance). Even modest weight loss has been shown to improve visceral adiposity and insulin resistance. There is a preferential loss of abdominal fat with aerobic exercise, as visceral adipocytes appear to respond more quickly to exercise-induced weight

loss than subcutaneous adipocytes (80). Regular endurance exercise may improve insulin sensitivity independent of total weight loss. Therefore, the aim of lifestyle modification therapy is to promote regular prolonged low intensity exercise (*i.e.* walking) to maintain weight and reduce visceral adipose tissue, rather than to set unobtainable weight loss goals.

Lipid lowering

Lifestyle changes may be inadequate to treat the dyslipidemia of the metabolic syndrome (increased TG, reduced HDL, and small dense LDL particles). Although LDL cholesterol has remained the primary target of lipid-lowering therapy, triglyceride lowering is an important secondary target to reduce CVD risk (11). Nicotinic acid and fibric acid derivatives both act to reduce TG and increase HDL cholesterol. They are frequently used with statin medications, but caution should be used in combining these drugs. Although niacin is an inexpensive monotherapeutic agent that corrects the combined dyslipidemia of the metabolic syndrome, it has the disadvantage of increasing glucose levels in some patients.

Recent evidence has suggested an underutilization of lipid-lowering therapy in women. Baseline data from the Heart and Estrogen/Progestin Replacement Study revealed that more than 60% of women with proven CVD did not meet the National Cholesterol Education Program goals for LDL lowering (81). It is also important to note that lipid abnormalities associated with the metabolic syndrome can be subtle. The metabolic syndrome is associated with small dense LDL particles, moderately elevated TG ($\geq$1.7 mmol/liter/ $\geq$150 mg/dl), and reduced HDL ($<$1.3 mmol/liter/$<$50 mg/ dl), but not elevated LDL cholesterol levels (Table 2) (11). There has been increasing interest in LDL and HDL particle size and composition as additional risk factors for atherosclerosis. Given that LDL levels may underestimate CVD risk in the presence of small dense LDL particles, practitioners must treat the dyslipidemia of the metabolic syndrome in addition to treating elevated LDL cholesterol levels. Measurement of LDL particle size may aid in identifying women at risk for CVD and targeting these women for aggressive lipid lowering.

Conclusion

CVD is the leading cause of death of women in developed countries, but very little is known about atherosclerotic disease progression in women. There has been recent emphasis on the metabolic syndrome as an atherosclerotic risk factor and its impact on CVD risk in women (11). Many of the features of the metabolic syndrome (central obesity and dyslipidemia with elevated TG, reduced HDL, and small dense LDL particles) emerge with estrogen deficiency in postmenopausal women, which may explain the acceleration of CVD in women after menopause. Accumulation of excess abdominal fat with transition through the menopause plays a central role in connecting the metabolic syndrome with the metabolic alterations of menopause and may account, in part, for the temporal separation in CVD risk between men and women (82).

It is unclear whether menopause is a cardiovascular risk factor for all women or only those who carry a predilection toward central adiposity. Endogenous estrogen appears to be cardioprotective, and postmenopausal estrogen deficiency unveils a constellation of closely associated adverse changes in metabolic risk factors. The emergence of these risk factors may be a direct result of ovarian failure or, alternatively, an indirect result of the metabolic consequences of central fat redistribution with estrogen deficiency. It is not clear whether the transition to menopause increases cardiovascular risk in all women or only those that develop the features of the metabolic syndrome. Women who develop insulin resistance with small, dense LDL and elevated PAI-1 after menopause may be carriers of a genetic predisposition that is masked by the effects of estrogen and unmasked after menopause. This subset of women may require targeted management to prevent future cardiovascular risk. Current evidence implies that multiple risk factors for CVD emerge in the postmenopausal period, but features of the metabolic syndrome may be present even before menopause. More research is clearly needed to further characterize the mechanisms by which women develop these metabolic changes with menopause.

References

1. **Rassouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J** 2002 Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288:321–333
2. **Burger HG, Dudley EC, Robertson DM, Dennerstein L** 2002 Hormonal changes in the menopause transition. Recent Prog Horm Res 57:257–275
3. **American Heart Association** 2001 Heart and stroke statistical update: American Heart Association. http://216.185.102.50/statistics/
4. **Gohlke-Barwolf C** 2000 Coronary artery disease: is menopause a risk factor? Basic Res Cardiol 95(Suppl 1):I77–I83
5. **Sutton-Tyrrell K, Lassila, HC, Meilahn E, Bunker C, Matthews KA, Kuller LH** 1998 Carotid atherosclerosis in premenopausal and postmenopausal women and its association with risk factors measured after menopause. Stroke 29:1116–1121
6. **Chambless LE, Heiss G, Folsom AR, Rosamond W, Szklo M, Sharrett AR, Clegg LX** 1997 Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: the Atherosclerosis Risk in Communities (ARIC) Study, 1987–1993. Am J Epidemiol 146:483–494
7. **Witteman JC, Grobbee DE, Kok FJ, Hofman A, Valkenburg HA** 1989 Increased risk of atherosclerosis in women after the menopause. Br Med J 298:642–644
8. **Janowitz WR, Agatston AS, Kaplan G, Viamonte Jr M** 1993 Differences in prevalence and extent of coronary artery calcium detected by ultrafast computed tomography in asymptomatic men and women. Am J Cardiol 72:247–254
9. **Kannel WB, Wilson PW** 1995 Risk factors that attenuate the female coronary disease advantage. Arch Intern Med 155:57–61
10. **Park YW, Zhu S, Palaniappan L, Heshka S, Carnethon MR, Heymsfield SB** 2003 The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988–1994. Arch Intern Med 163:427–436
11. **National Cholesterol Education Program** 2001 Executive Summary of the third report of the National Cholesterol Education Program (NCEP) expert

panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 285:2486–2497

12. **Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, Salonen JT** 2002 The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 288:2709–2716

13. **Despres JP** 1993 Abdominal obesity as important component of insulin-resistance syndrome. Nutrition 9:452–459

14. **Meigs JB** 2002 Epidemiology of the metabolic syndrome, 2002. Am J Manag Care 8(Suppl 11):S283–S296

15. **Wilson PW, Kannel WB, Silbershatz H, D'Agostino RB** 1999 Clustering of metabolic factors and coronary heart disease. Arch Intern Med 159:1104–1109

16. **Reaven GM** 1988 Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 37:1595–1607

17. **Vague J** 1956 The degree of masculine differentiation of obesities: a factor determining predisposition to diabetes, atherosclerosis, gout, and uric calculous disease. Am J Clin Nutr 4:20

18. **Selby JV, Newman B, Quiroga J, Christian JC, Austin MA, Fabsitz RR** 1991 Concordance for dyslipidemic hypertension in male twins. JAMA 265:2079–2084

19. **Bouchard C** 1995 Genetics and the metabolic syndrome. Int J Obes Relat Metab Disord 19(Suppl 1):S52–S59

20. **Kannel WB, Cupples LA, Ramaswami R, Stokes JD, Kreger BE, Higgins M** 1991 Regional obesity and risk of cardiovascular disease; the Framingham Study. J Clin Epidemiol 44:183–190

21. **Krotkiewski M, Bjorntorp P, Sjostrom L, Smith U** 1983 Impact of obesity on metabolism in men and women. Importance of regional adipose tissue distribution. J Clin Invest 72:1150–1162

22. **Poehlman ET, Toth MJ, Gardner AW** 1995 Changes in energy balance and body composition at menopause: a controlled longitudinal study. Ann Intern Med 123:673–675

23. **Poehlman ET, Toth MJ, Ades PA, Rosen CJ** 1997 Menopause-associated changes in plasma lipids, insulin-like growth factor I and blood pressure: a longitudinal study. Eur J Clin Invest 27:322–326

24. **Crawford SL, Casey VA, Avis NE, McKinlay SM** 2000 A longitudinal study of weight and the menopause transition: results from the Massachusetts Women's Health Study. Menopause 7:96–104

25. **Guo SS, Zeller C, Chumlea WC, Siervogel RM** 1999 Aging, body composition, and lifestyle: the Fels Longitudinal Study. Am J Clin Nutr 70:405–411

26. **Kuller L, Meilahn E, Lassila H, Matthews K, Wing R** 1997 Cardiovascular risk factors during first five years postmenopause in nonhormone replacement users. In: Forte T, ed. Hormonal, metabolic, and cellular influences on cardiovascular disease in women. Armonk: Futura; 273–287

27. **Zamboni M, Armellini F, Milani MP, De Marchi M, Todesco T, Robbi R, Bergamo-Andreis IA, Bosello O** 1992 Body fat distribution in pre- and postmenopausal women: metabolic and anthropometric variables and their interrelationships. Int J Obes Relat Metab Disord 16:495–504

28. **Bjorkelund C, Lissner L, Andersson S, Lapidus L, Bengtsson C** 1996 Reproductive history in relation to relative weight and fat distribution. Int J Obes Relat Metab Disord 20:213–219

29. **Toth MJ, Tchernof A, Sites CK, Poehlman ET** 2000 Effect of menopausal status on body composition and abdominal fat distribution. Int J Obes Relat Metab Disord 24:226–231

30. **Carr MC, Brunzell JD,** Increased hepatic lipase activity and intraabdominal fat across the transition from pre- to postmenopause. Program of the 85th Annual Meeting of The Endocrine Society, Philadelphia, PA, 2003 (Abstract P2-280)

31. **Lapidus L, Bengtsson C, Larsson B, Pennert K, Rybo E, Sjostrom L** 1984 Distribution of adipose tissue and risk of cardiovascular disease and death: a 12 year follow up of participants in the population study of women in Gothenburg, Sweden. Br Med J 289:1257–1261

32. **Pascot A, Despres JP, Lemieux I, Almeras N, Bergeron J, Nadeau A, Prud'homme D, Tremblay A, Lemieux S** 2001 Deterioration of the metabolic risk profile in women. Respective contributions of impaired glucose tolerance and visceral fat accumulation. Diabetes Care 24:902–908

33. **Ferrara CM, Lynch NA, Nicklas BJ, Ryan AS, Berman DM** 2002 Differences in adipose tissue metabolism between postmenopausal and perimenopausal women. J Clin Endocrinol Metab 87:4166–4170

34. **Mauriege P, Imbeault P, Prud'Homme D, Tremblay A, Nadeau A, Despres JP** 2000 Subcutaneous adipose tissue metabolism at menopause: importance of body fatness and regional fat distribution. J Clin Endocrinol Metab 85:2446–2454

35. **Nishizawa H, Shimomura I, Kishida K, Maeda N, Kuriyama H, Nagaretani H, Matsuda M, Kondo H, Furuyama N, Kihara S, Nakamura T, Tochino Y, Funahashi T, Matsuzawa Y** 2002 Androgens decrease plasma adiponectin, an insulin-sensitizing adipocyte-derived protein. Diabetes 51:2734–2741

36. **Poehlman ET** 2002 Menopause, energy expenditure, and body composition. Acta Obstet Gynecol Scand 81:603–611

37. **Lynch NA, Ryan AS, Berman DM, Sorkin JD, Nicklas BJ,** Comparison of VO₂max and disease risk factors between perimenopausal and postmenopausal women. Menopause 9:456–462

38. **Jensen J, Nilas L, Christiansen C** 1990 Influence of menopause on serum lipids and lipoproteins. Maturitas 12:321–331

39. **Campos H, McNamara JR, Wilson PW, Ordovas JM, Schaefer EJ** 1988 Differences in low density lipoprotein subfractions and apolipoproteins in premenopausal and postmenopausal women. J Clin Endocrinol Metab 67:30–35

40. **Li Z, McNamara JR, Fruchart JC, Luc G, Bard JM, Ordovas JM, Wilson PW, Schaefer EJ** 1996 Effects of gender and menopausal status on plasma lipoprotein subspecies and particle sizes. J Lipid Res 37:1886–1896

41. **Matthews KA, Meilahn E, Kuller LH, Kelsey SF, Caggiula AW, Wing RR** 1989 Menopause and risk factors for coronary heart disease. N Engl J Med 321:641–646

42. **Matthews KA, Kuller LH, Sutton-Tyrrell K, Chang YF** 2001 Changes in cardiovascular risk factors during the perimenopause and postmenopause and carotid artery atherosclerosis in healthy women. Stroke 32:1104–1111

43. **Austin M, King M-C, Vranizan K, Newman B, Krauss R** 1988 Inheritance of low density lipoprotein subclass patterns: results of complex segregation analysis. Am J Hum Genet 43:838–846

44. **Carr MC, Kim KH, Zambon A, Mitchell ES, Woods NF, Casazza CP, Purnell JQ, Hokanson JE, Brunzell JD, Schwartz RS** 2000 Changes in LDL density across the menopausal transition. J Invest Med 48:245–250

45. **Austin M, Breslow J, Hennekens C, Buring J, Willett W, Krauss R** 1988 Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA 260:1917–1921

46. **Campos H, Genest JJ, Blijlevens E, McNamara JR, Jenner JL, Ordovas JM, Wilson PW, Schaefer EJ** 1992 Low density lipoprotein particle size and coronary artery disease. Arterioscler Thromb 12:187–195

47. **Mackey RH, Kuller LH, Sutton-Tyrrell K, Evans RW, Holubkov R, Matthews KA** 2002 Lipoprotein subclasses and coronary artery calcium in postmenopausal women from the healthy women study. Am J Cardiol 90:71i–76i

48. **Razay G, Heaton KW, Bolton CH** 1992 Coronary heart disease risk factors in relation to the menopause. Q J Med 85:889–896

49. **Hokanson JE, Austin MA** 1996 Plasma triglyceride is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 3:213–219

50. **Lindquist O** 1982 Intraindividual changes of blood pressure, serum lipids, and body weight in relation to menstrual status: results from a prospective population study of women in Goteborg, Sweden. Prev Med 11:162–172

51. **Do KA, Green A, Guthrie JR, Dudley EC, Burger HG, Dennerstein L** 2000 Longitudinal study of risk factors for coronary heart disease across the menopausal transition. Am J Epidemiol 151:584–593

52. **Kannel WB, Hjortland MC, McNamara PM, Gordon T** 1976 Menopause and risk of cardiovascular disease: the Framingham study. Ann Intern Med 85:447–452

53. **Stevenson JC, Crook D, Godsland IF** 1993 Influence of age and menopause on serum lipids and lipoproteins in healthy women. Atherosclerosis 98:83–90

54. **Lamarche B, Moorjani S, Cantin B, Dagenais GR, Lupien PJ, Despres JP** 1997 Associations of HDL2 and HDL3 subfractions with ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study. Arterioscler Thromb Vasc Biol 17:1098–1105

55. **Shlipak MG, Simon JA, Vittinghoff E, Lin F, Barrett-Connor E, Knopp RH, Levy RI, Hulley SB** 2000 Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause. JAMA 283:1845–1852

56. **Jenner JL, Ordovas JM, Lamon-Fava S, Schaefer MM, Wilson PW, Castelli WP, Schaefer EJ** 1993 Effects of age, sex, and menopausal status on plasma lipoprotein(a) levels. The Framingham Offspring Study. Circulation 87:1135–1141

57. **Bruschi F, Meschia M, Soma M, Perotti D, Paoletti R, Crosignani PG** 1996 Lipoprotein(a) and other lipids after oophorectomy and estrogen replacement therapy. Obstet Gynecol 88:950–954

58. **Berg GA, Siseles N, Gonzalez AI, Ortiz OC, Tempone A, Wikinski RW** 2001 Higher values of hepatic lipase activity in postmenopause: relationship with atherogenic intermediate density and low density lipoproteins. Menopause 8:51–57

59. **Tikkanen MJ, Kuusi T, Nikkila EA, Stenman UH** 1986 Variation of post-heparin plasma hepatic lipase by menstrual cycle. Metabolism 35:99–104

60. **Santamarina-Fojo S, Haudenschild C, Amar M** 1998 The role of hepatic lipase in lipoprotein metabolism and atherosclerosis. Curr Opin Lipidol 9:211–219

61. **Lewis-Barned NJ, Sutherland WH, Walker RJ, Walker HL, De Jong SA, Edwards EA, Markham VH** 1999 Plasma cholesterol esterification and transfer, the menopause, and hormone replacement therapy in women. J Clin Endocrinol Metab 84:3534–3538

62. **Pouliot MC, Despres JP, Nadeau A, Moorjani S, Prud'Homme D, Lupien PJ, Tremblay A, Bouchard C** 1992 Visceral obesity in men. Associations with glucose tolerance, plasma insulin, and lipoprotein levels. Diabetes 41:826–834

63. **Dallongeville J, Marecaux N, Isorez D, Zylbergberg G, Fruchart JC, Amouyel P** 1995 Multiple coronary heart disease risk factors are associated with menopause and influenced by substitutive hormonal therapy in a cohort of French women. Atherosclerosis 118:123–133

64. **Lindheim SR, Buchanan TA, Duffy DM, Vijod MA, Kojima T, Stanczyk FZ, Lobo RA** 1994 Comparison of estimates of insulin sensitivity in pre- and postmenopausal women using the insulin tolerance test and the frequently sampled intravenous glucose tolerance test. J Soc Gynecol Invest 1:150–154

65. **Walton C, Godsland IF, Proudler AJ, Wynn V, Stevenson JC** 1993 The effects of the menopause on insulin sensitivity, secretion and elimination in nonobese, healthy women. Eur J Clin Invest 23:466–473

66. **Toth MJ, Sites CK, Eltabbakh GH, Poehlman ET** 2000 Effect of menopausal status on insulin-stimulated glucose disposal: comparison of middle-aged premenopausal and early postmenopausal women. Diabetes Care 23:801–806

67. **DeNino WF, Tchernof A, Dionne IJ, Toth MJ, Ades PA, Sites CK, Poehlman ET** 2001 Contribution of abdominal adiposity to age-related differences in insulin sensitivity and plasma lipids in healthy nonobese women. Diabetes Care 24:925–932

68. **Guthrie JR, Ball M, Dudley EC, Garamszegi CV, Wahlqvist ML, Dennerstein L, Burger HG** 2001 Impaired fasting glycaemia in middle-aged women: a prospective study. Int J Obes Relat Metab Disord 25:646–651

69. **Juhan-Vague I, Pyke SD, Alessi MC, Jespersen J, Haverkate F, Thompson SG** 1996 Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. ECAT Study Group. European Concerted Action on Thrombosis and Disabilities. Circulation 94:2057–2063

70. **Ridker PM, Vaughan DE, Stampfer MJ, Manson JE, Hennekens CH** 1993 Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet 341:1165–1168

71. **Landin K, Stigendal L, Eriksson E, Krotkiewski M, Risberg B, Tengborn L, Smith U** 1990 Abdominal obesity is associated with an impaired fibrinolytic activity and elevated plasminogen activator inhibitor-1. Metabolism 39:1044–1048

72. **Lindoff C, Petersson F, Lecander I, Martinsson G, Astedt B** 1993 Passage of the menopause is followed by haemostatic changes. Maturitas 17:17–22

73. **Gebara OC, Mittleman MA, Sutherland P, Lipinska I, Matheney T, Xu P, Welty FK, Wilson PW, Levy D, Muller JE, Tofler GH** 1995 Association between increased estrogen status and increased fibrinolytic potential in the Framingham Offspring Study. Circulation 91:1952–1958

74. **Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH** 1998 Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 98:731–733

75. **Tchernof A, Nolan A, Sites CK, Ades PA, Poehlman ET** 2002 Weight loss reduces C-reactive protein levels in obese postmenopausal women. Circulation 105:564–569

76. **Sites CK, Toth MJ, Cushman M, L'Hommedieu GD, Tchernof A, Tracy RP, Poehlman ET** 2002 Menopause-related differences in inflammation markers and their relationship to body fat distribution and insulin-stimulated glucose disposal. Fertil Steril 77:128–135

77. **Harris TB, Ferrucci L, Tracy RP, Corti MC, Wacholder S, Ettinger Jr WH, Heimovitz H, Cohen HJ, Wallace R** 1999 Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am J Med 106:506–512

78. **Pradhan AD, Manson JE, Rossouw JE, Siscovick DS, Mouton CP, Rifai N, Wallace RB, Jackson RD, Pettinger MB, Ridker PM** 2002 Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: prospective analysis from the Women's Health Initiative observational study. JAMA 288:980–987

79. **Pfeilschifter J, Koditz R, Pfohl M, Schatz H** 2002 Changes in proinflammatory cytokine activity after menopause. Endocr Rev 23:90–119

80. **Despres JP, Pouliot MC, Moorjani S, Nadeau A, Tremblay A, Lupien PJ, Theriault G, Bouchard C** 1991 Loss of abdominal fat and metabolic response to exercise training in obese women. Am J Physiol 261:E159–E167

81. **Schrott HG, Bittner V, Vittinghoff E, Herrington DM, Hulley S** 1997 Adherence to National Cholesterol Education Program Treatment goals in postmenopausal women with heart disease. The Heart and Estrogen/Progestin Replacement Study (HERS). The HERS Research Group. JAMA 277:1281–1286

82. **Larsson B, Bengtsson C, Bjorntorp P, Lapidus L, Sjostrom L, Svardsudd K, Tibblin G, Wedel H, Welin L, Wilhelmsen L** 1992 Is abdominal body fat distribution a major explanation for the sex difference in the incidence of myocardial infarction? The study of men born in 1913 and the study of women, Goteborg, Sweden. Am J Epidemiol 135:266–273